Parkinson Disease-Mediated Gastrointestinal Disorders and Rational for Combinatorial Therapies
Abstract
:1. Introduction
PD Associated GI Dysfunctions
2. Prognostic Implications
3. Stem Cell-Mediated Therapy in PD
4. Combination Therapies: A Rational for Neuroprotection
Acknowledgments
Conflicts of Interest
References
- De Lau, L.M.; Breteler, M.M. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006, 5, 525–535. [Google Scholar] [CrossRef]
- Giladi, N.; McDermott, M.P.; Fahn, S.; Przedborski, S.; Jankovic, J.; Stern, M.; Tanner, C.; Parkinson Study Group. Freezing of gait in PD: Prospective assessment in the DATATOP cohort. Neurology 2001, 56, 1712–1721. [Google Scholar] [CrossRef] [PubMed]
- Lees, A.J.; Hardy, J.; Revesz, T. Parkinson’s disease. Lancet 2009, 373, 2055–2066. [Google Scholar] [CrossRef]
- Klockgether, T. Parkinson’s disease: Clinical aspects. Cell Tissue Res. 2004, 318, 115–120. [Google Scholar] [CrossRef] [PubMed]
- Larson, P.S. Deep Brain Stimulation for Movement Disorders. Neurotherapeutics 2014, 11, 465–474. [Google Scholar] [CrossRef] [PubMed]
- Thevathasan, W.; Aziz, T. Predicting falls in Parkinson disease: A step in the right direction. Neurology 2010, 75, 107–108. [Google Scholar] [CrossRef] [PubMed]
- Hely, M.A.; Reid, W.G.; Adena, M.A.; Halliday, G.M.; Morris, J.G. The Sydney multicenter study of Parkinson’s disease: The inevitability of dementia at 20 years. Mov. Disord. 2008, 23, 837–844. [Google Scholar] [CrossRef] [PubMed]
- Schenck, C.H.; Bundlie, S.R.; Ettinger, M.G.; Mahowald, M.W. Chronic behavioral disorders of human REM sleep: A new category of parasomnia. Sleep 1986, 9, 293–308. [Google Scholar] [PubMed]
- Aarsland, D.; Brønnick, K.; Ehrt, U.; de Deyn, P.P.; Tekin, S.; Emre, M.; Cummings, J.L. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: Frequency, profile and associated care giver stress. J. Neurol. Neurosurg. Psychiatry 2007, 78, 36–42. [Google Scholar] [CrossRef] [PubMed]
- Chaudhuri, K.R.; Healy, D.G.; Schapira, A.H. National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol. 2006, 5, 235–245. [Google Scholar] [CrossRef]
- Sethi, K.D. Clinical aspects of Parkinson disease. Curr. Opin. Neurol. 2002, 15, 457–460. [Google Scholar] [CrossRef] [PubMed]
- Ferrer, I.; Martinez, A.; Blanco, R.; Dalfó, E.; Carmona, M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: Preclinical Parkinson disease. J. Neural Transm. 2011, 118, 821–839. [Google Scholar] [CrossRef] [PubMed]
- Cloud, L.J.; Greene, J.G. Gastrointestinal Features of Parkinson’s Disease. Curr. Neurol. Neurosci. Rep. 2011, 11, 379–384. [Google Scholar] [CrossRef] [PubMed]
- Pfeiffer, R.F. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2003, 2, 107–116. [Google Scholar] [CrossRef]
- Sung, H.Y.; Park, J.W.; Kim, J.S. The frequency and severity of gastrointestinal symptoms in patients with early Parkinson’s disease. J. Mov. Disord. 2014, 7, 7–12. [Google Scholar] [CrossRef] [PubMed]
- Cersosimo, M.G.; Raina, G.B.; Pecci, C.; Pellene, A.; Calandra, C.R.; Gutiérrez, C.; Micheli, F.E.; Benarroch, E.E. Gastrointestinal manifestations in Parkinson’s disease: Prevalence and occurrence before motor symptoms. J. Neurol. 2013, 260, 1332–1338. [Google Scholar] [CrossRef] [PubMed]
- Makaroff, L.; Gunn, A.; Gervasoni, C.; Richy, F. Gastrointestinal disorders in Parkinson’s disease: Prevalence and health outcomes in a US claims database. J. Parkinsons Dis. 2011, 1, 65–74. [Google Scholar] [PubMed]
- Potulska, A.; Friedman, A.; Królicki, L.; Spychala, A. Swallowing disorders in Parkinson’s disease. Parkinsonism Relat. Disord. 2003, 9, 349–353. [Google Scholar] [CrossRef]
- Abbott, R.A.; Cox, M.; Markus, H.; Tomkins, A. Diet, body size and micronutrient status in Parkinson’s disease. Eur. J. Clin. Nutr. 1992, 46, 879–884. [Google Scholar] [PubMed]
- Bachmann, C.G.; Trenkwalder, C. Body weight in patients with Parkinson’s disease. Mov. Disord. 2006, 21, 1824–1830. [Google Scholar] [CrossRef] [PubMed]
- Durrieu, G.; Lau, M.E.; Rascol, O.; Senard, J.M.; Rascol, A.; Montastruc, J.L. Parkinson’s disease and weight loss: A study with anthropometric and nutritional assessment. Clin. Auton. Res. 1992, 2, 153–157. [Google Scholar] [CrossRef] [PubMed]
- Moro, E.; Scerrati, M.; Romito, L.M.; Roselli, R.; Tonali, P.; Albanese, A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson’s disease. Neurology 1999, 53, 85–90. [Google Scholar] [CrossRef] [PubMed]
- Eadie, M.J.; Tyrer, J.H. Alimentary Disorder in Parkinsonism. Australas. Ann. Med. 1965, 14, 13–22. [Google Scholar] [PubMed]
- Edwards, L.L.; Pfeiffer, R.F.; Quigley, E.M.; Hofman, R.; Balluff, M. Gastrointestinal symptoms in Parkinson’s disease. Mov. Disord. 1991, 6, 151–156. [Google Scholar] [CrossRef] [PubMed]
- Mendonca, L.S.; Nóbrega, C.; Hirai, H.; Kaspar, B.K.; Pereira de Almeida, L. Transplantation of cerebellar neural stem cells improves motor coordination and neuropathology in Machado-Joseph disease mice. Brain 2015, 138, 320–335. [Google Scholar] [CrossRef] [PubMed]
- Zlotnik, Y.; Balash, Y.; Korczyn, A.D.; Giladi, N.; Gurevich, T. Disorders of the oral cavity in Parkinson’s disease and parkinsonian syndromes. Parkinsons Dis. 2015, 2015, 379–482. [Google Scholar] [CrossRef] [PubMed]
- Kalf, J.G.; Bloem, B.R.; Munneke, M. Diurnal and nocturnal drooling in Parkinson’s disease. J. Neurol. 2012, 259, 119–123. [Google Scholar] [CrossRef] [PubMed]
- Tumilasci, O.R.; Cersósimo, M.G.; Belforte, J.E.; Micheli, F.E.; Benarroch, E.E.; Pazo, J.H. Quantitative study of salivary secretion in Parkinson’s disease. Mov. Disord. 2006, 21, 660–667. [Google Scholar] [CrossRef] [PubMed]
- Wernig, M.; Zhao, J.P.; Pruszak, J.; Hedlund, E.; Fu, D.; Soldner, F.; Broccoli, V.; Constantine-Paton, M.; Isacson, O.; Jaenisch, R. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson’s disease. Proc. Natl. Acad. Sci. USA 2008, 105, 5856–5861. [Google Scholar] [CrossRef] [PubMed]
- Chou, K.L.; Evatt, M.; Hinson, V.; Kompoliti, K. Sialorrhea in Parkinson’s disease: A review. Mov. Disord. 2007, 22, 2306–2313. [Google Scholar] [CrossRef] [PubMed]
- Hyson, H.C.; Johnson, A.M.; Jog, M.S. Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study. Mov. Disord. 2002, 17, 1318–1320. [Google Scholar] [CrossRef] [PubMed]
- Ondo, W.G.; Hunter, C.; Moore, W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 2004, 62, 37–40. [Google Scholar] [CrossRef] [PubMed]
- Salat-Foix, D.; Suchowersky, O. The management of gastrointestinal symptoms in Parkinson’s disease. Expert Rev. Neurother. 2012, 12, 239–248. [Google Scholar] [CrossRef] [PubMed]
- Thomsen, T.R.; Galpern, W.R.; Asante, A.; Arenovich, T.; Fox, S.H. Ipratropium bromide spray as treatment for sialorrhea in Parkinson’s disease. Mov Disord. 2007, 22, 2268–2273. [Google Scholar] [CrossRef] [PubMed]
- Ertekin, C. Electrophysiological evaluation of oropharyngeal Dysphagia in Parkinson’s disease. J. Mov. Disord. 2014, 7, 31–56. [Google Scholar] [CrossRef] [PubMed]
- Stroudley, J.; Walsh, M. Radiological assessment of dysphagia in Parkinson’s disease. Br. J. Radiol. 1991, 64, 890–893. [Google Scholar] [CrossRef] [PubMed]
- Wakabayashi, K.; Takahashi, H.; Takeda, S.; Ohama, E.; Ikuta, F. Parkinson’s disease: The presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathol. 1988, 76, 217–221. [Google Scholar] [CrossRef] [PubMed]
- Cereda, E.; Cilia, R.; Klersy, C.; Canesi, M.; Zecchinelli, A.L.; Mariani, C.B.; Tesei, S.; Sacilotto, G.; Meucci, N.; Zini, M.; et al. Swallowing disturbances in Parkinson’s disease: A multivariate analysis of contributing factors. Parkinsonism Relat. Disord. 2014, 20, 1382–1387. [Google Scholar] [CrossRef] [PubMed]
- Leopold, N.A.; Kagel, M.C. Prepharyngeal dysphagia in Parkinson’s disease. Dysphagia 1996, 11, 14–22. [Google Scholar] [CrossRef] [PubMed]
- Muller, J.; Wenning, G.K.; Verny, M.; McKee, A.; Chaudhuri, K.R.; Jellinger, K.; Poewe, W.; Litvan, I. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch. Neurol. 2001, 58, 259–264. [Google Scholar] [CrossRef] [PubMed]
- Sung, H.Y.; Kim, J.S.; Lee, K.S.; Kim, Y.I.; Song, I.U.; Chung, S.W.; Yang, D.W.; Cho, Y.K.; Park, J.M.; Lee, I.S.; et al. The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson’s disease. Mov. Disord. 2010, 25, 2361–2368. [Google Scholar] [CrossRef] [PubMed]
- Alfonsi, E.; Versino, M.; Merlo, I.M.; Pacchetti, C.; Martignoni, E.; Bertino, G.; Moglia, A.; Tassorelli, C.; Nappim, G. Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes. Neurology 2007, 68, 583–589. [Google Scholar] [CrossRef] [PubMed]
- Leopold, N.A.; Kagel, M.C. Laryngeal deglutition movement in Parkinson’s disease. Neurology 1997, 48, 373–376. [Google Scholar] [CrossRef] [PubMed]
- Lim, A.; Leow, L.; Huckabee, M.L.; Frampton, C.; Anderson, T. A pilot study of respiration and swallowing integration in Parkinson’s disease: “on” and “off” levodopa. Dysphagia 2008, 23, 76–81. [Google Scholar] [CrossRef] [PubMed]
- Fuh, J.L.; Lee, R.C.; Wang, S.J.; Lin, C.H.; Wang, P.N.; Chiang, J.H.; Liu, H.C. Swallowing difficulty in Parkinson’s disease. Clin. Neurol. Neurosurg. 1997, 99, 106–112. [Google Scholar] [CrossRef]
- McCallum, S.L. The National Dysphagia Diet: Implementation at a regional rehabilitation center and hospital system. J. Am. Diet. Assoc. 2003, 103, 381–384. [Google Scholar] [CrossRef] [PubMed]
- Tison, F.; Wiart, L.; Guatterie, M.; Fouillet, N.; Lozano, V.; Henry, P.; Barat, M. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson’s disease. Mov. Disord. 1996, 11, 729–732. [Google Scholar] [CrossRef] [PubMed]
- Braak, H.; de Vos, R.A.; Bohl, J.; del Tredici, K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci. Lett. 2006, 396, 67–72. [Google Scholar] [CrossRef] [PubMed]
- Hardoff, R.; Sula, M.; Tamir, A.; Soil, A.; Front, A.; Badarna, S.; Honigman, S.; Giladi, N. Gastric emptying time and gastric motility in patients with Parkinson’s disease. Mov. Disord. 2001, 16, 1041–1047. [Google Scholar] [CrossRef] [PubMed]
- Annese, V.; Janssens, J.; Vantrappen, G.; Tack, J.; Peeters, T.L.; Willemse, P.; van Cutsem, E. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology 1992, 102, 823–828. [Google Scholar] [PubMed]
- Lertxundi, U.; Domingo-Echaburu, S.; Soraluce, A.; García, M.; Ruiz-Osante, B.; Aguirre, C. Domperidone in Parkinson’s disease: A perilous arrhythmogenic or the gold standard? Curr. Drug Saf. 2013, 8, 63–68. [Google Scholar] [CrossRef] [PubMed]
- Rossi, M.; Giorgi, G. Domperidone and long QT syndrome. Curr. Drug Saf. 2010, 5, 257–262. [Google Scholar] [CrossRef] [PubMed]
- Gasbarrini, A.; Lauritano, E.C.; Gabrielli, M.; Scarpellini, E.; Lupascu, A.; Ojetti, V.; Gasbarrini, G. Small intestinal bacterial overgrowth: Diagnosis and treatment. Dig. Dis. 2007, 25, 237–240. [Google Scholar] [CrossRef] [PubMed]
- Dobbs, R.J.; Charlett, A.; Dobbs, S.M.; Weller, C.; Ibrahim, M.A.; Iguodala, O.; Smee, C.; Plant, J.M.; Lawson, A.J.; Taylor, D.; et al. Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut Pathog. 2012, 4, 12. [Google Scholar] [CrossRef] [PubMed]
- Dobbs, S.M.; Charlett, A.; Dobbs, R.J.; Weller, C.; Iguodala, O.; Smee, C.; Lawson, A.J.; Taylor, D.; Bjarnason, I. Antimicrobial surveillance in idiopathic parkinsonism: Indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity. Helicobacter 2013, 18, 187–196. [Google Scholar] [CrossRef] [PubMed]
- Gabrielli, M.; Bonazzi, P.; Scarpellini, E.; Bendia, E.; Lauritano, E.C.; Fasano, A.; Ceravolo, M.G.; Capecci, M.; Bentivoglio, A.R.; Provinciali, L.; et al. Prevalence of small intestinal bacterial overgrowth in Parkinson’s disease. Mov. Disord. 2011, 26, 889–892. [Google Scholar] [CrossRef] [PubMed]
- Parlesak, A.; Klein, B.; Schecher, K.; Bode, J.C.; Bode, C. Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults. J. Am. Geriatr. Soc. 2003, 51, 768–773. [Google Scholar] [CrossRef] [PubMed]
- Tan, A.H.; Mahadeva, S.; Thalha, A.M.; Gibson, P.R.; Kiew, C.K.; Yeat, C.M.; Ng, S.W.; Ang, S.P.; Chow, S.K.; Tan, C.T. Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat. Disord. 2014, 20, 535–540. [Google Scholar] [CrossRef] [PubMed]
- Fasano, A.; Bove, F.; Gabrielli, M.; Petracca, M.; Zocco, M.A.; Ragazzoni, E.; Barbaro, F.; Piano, C.; Fortuna, S.; Tortora, A.; et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov. Disord. 2013, 28, 1241–1249. [Google Scholar] [CrossRef] [PubMed]
- Edwards, L.L.; Quigley, E.M.; Harned, R.K.; Hofman, R.; Pfeiffer, R.F. Defecatory function in Parkinson’s disease: Response to apomorphine. Ann Neurol. 1993, 33, 490–493. [Google Scholar] [CrossRef] [PubMed]
- Jost, W.H.; Schimrigk, K. Constipation in Parkinson’s disease. Klin. Wochenschr. 1991, 69, 906–909. [Google Scholar] [CrossRef] [PubMed]
- Sakakibara, R.; Odaka, T.; Uchiyama, T.; Asahina, M.; Yamaguchi, K.; Yamaguchi, T.; Yamanishi, T.; Hattori, T. Colonic transit time and rectoanal videomanometry in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 2003, 74, 268–272. [Google Scholar] [CrossRef] [PubMed]
- Ashraf, W.; Wszolek, Z.K.; Pfeiffer, R.F.; Normand, M.; Maurer, K.; Srb, F.; Edwards, L.L.; Quigley, E.M. Anorectal function in fluctuating (on-off) Parkinson’s disease: Evaluation by combined anorectal manometry and electromyography. Mov. Disord. 1995, 10, 650–657. [Google Scholar] [CrossRef] [PubMed]
- Wakabayashi, K.; Takahashi, H.; Ohama, E.; Takeda, S.; Ikuta, F. Lewy bodies in the visceral autonomic nervous system in Parkinson’s disease. Adv. Neurol. 1993, 60, 609–612. [Google Scholar] [PubMed]
- Abbott, R.D.; Petrovitch, H.; White, L.R.; Masaki, K.H.; Tanner, C.M.; Curb, J.D.; Grandinetti, A.; Blanchette, P.L.; Popper, J.S.; Ross, G.W. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001, 57, 456–462. [Google Scholar] [CrossRef] [PubMed]
- Abbott, R.D.; Ross, G.W.; Petrovitch, H.; Tanner, C.M.; Davis, D.G.; Masaki, K.H.; Launer, L.J.; Curb, J.D.; White, L.R. Bowel movement frequency in late-life and incidental Lewy bodies. Mov. Disord. 2007, 22, 1581–1586. [Google Scholar] [CrossRef] [PubMed]
- Petrovitch, H.; Abbott, R.D.; Ross, G.W.; Nelson, J.; Masaki, K.H.; Tanner, C.M.; Launer, L.J.; White, L.R. Bowel movement frequency in late-life and substantia nigra neuron density at death. Mov. Disord. 2009, 24, 371–376. [Google Scholar] [CrossRef] [PubMed]
- Ashraf, W.; Pfeiffer, R.F.; Park, F.; Lof, J.; Quigley, E.M. Constipation in Parkinson’s disease: Objective assessment and response to psyllium. Mov. Disord. 1997, 12, 946–951. [Google Scholar] [CrossRef] [PubMed]
- Zangaglia, R.; Martignoni, E.; Glorioso, M.; Ossola, M.; Riboldazzi, G.; Calandrella, D.; Brunetti, G.; Pacchetti, C. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov. Disord. 2007, 22, 1239–1244. [Google Scholar] [CrossRef] [PubMed]
- Bassotti, G.; Maggio, D.; Battaglia, E.; Giulietti, O.; Spinozzi, F.; Reboldi, G.; Serra, A.M.; Emanuelli, G.; Chiarioni, G. Manometric investigation of anorectal function in early and late stage Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 2000, 68, 768–770. [Google Scholar] [CrossRef] [PubMed]
- Mathers, S.E.; Kempster, P.A.; Law, P.J.; Frankel, J.P.; Bartram, C.I.; Lees, A.J.; Stern, G.M.; Swash, M. Anal Sphincter dysfunction in Parkinson’s disease. Arch. Neurol. 1989, 46, 1061–1064. [Google Scholar] [CrossRef] [PubMed]
- Mathers, S.E.; Kempster, P.A.; Swash, M.; Lees, A.J. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: A dystonic phenomenon? J. Neurol. Neurosurg. Psychiatry 1988, 51, 1503–1507. [Google Scholar] [CrossRef] [PubMed]
- Glenn, J.D.; Whartenby, K.A. Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World J. Stem Cells 2014, 6, 526–539. [Google Scholar] [CrossRef] [PubMed]
- Guo, K.; Ikehara, S.; Meng, X. Mesenchymal stem cells for inducing tolerance in organ transplantation. Front. Cell Dev. Biol. 2014, 2, 8. [Google Scholar] [CrossRef] [PubMed]
- Beach, T.G.; Adler, C.H.; Sue, L.I.; Vedders, L.; Lue, L.; White, C.L.; Akiyama, H.; Caviness, J.N.; Shill, H.A.; Sabbagh, M.N. Arizona Parkinson’s Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010, 119, 689–702. [Google Scholar] [CrossRef] [PubMed]
- Lebouvier, T.; Chaumette, T.; Paillusson, S.; Duyckaerts, C.; Bruley des Varannes, S.; Neunlist, M.; Derkinderen, P. The second brain and Parkinson’s disease. Eur. J. Neurosci. 2009, 30, 735–741. [Google Scholar] [CrossRef] [PubMed]
- Anlauf, M.; Schäfer, M.K.; Eiden, L.; Weihe, E. Chemical coding of the human gastrointestinal nervous system: Cholinergic, VIPergic, and catecholaminergic phenotypes. J. Comp. Neurol. 2003, 459, 90–111. [Google Scholar] [CrossRef] [PubMed]
- Derkinderen, P.; Rouaud, T.; Lebouvier, T.; Bruley des Varannes, S.; Neunlist, M.; de Giorgio, R. Parkinson disease: The enteric nervous system spills its guts. Neurology 2011, 77, 1761–1767. [Google Scholar] [CrossRef] [PubMed]
- Visanji, N.P.; Marras, C.; Hazrati, L.N.; Liu, L.W.; Lang, A.E. Alimentary, my dear Watson? The challenges of enteric alpha-synuclein as a Parkinson’s disease biomarker. Mov. Disord. 2014, 29, 444–450. [Google Scholar] [CrossRef] [PubMed]
- Miller, D.B.; O’Callaghan, J.P. Biomarkers of Parkinson’s disease: Present and future. Metabolism 2015, 64, S40–S46. [Google Scholar] [CrossRef] [PubMed]
- Kashiwaya, Y.; Takeshima, T.; Mori, N.; Nakashima, K.; Clarke, K.; Veech, R.L. d-beta-hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s disease. Proc. Natl. Acad. Sci. USA 2000, 97, 5440–5444. [Google Scholar] [CrossRef] [PubMed]
- Feng, D.D.; Cai, W.; Chen, X. The associations between Parkinson’s disease and cancer: The plot thickens. Transl. Neurodegener. 2015, 4, 20. [Google Scholar] [CrossRef] [PubMed]
- Frattini, E.; Ruggieri, M.; Salani, S.; Faravelli, I.; Zanetta, C.; Nizzardo, M.; Simone, C.; Magri, F.; Corti, S. Pluripotent stem cell-based models of spinal muscular atrophy. Mol. Cell. Neurosci. 2015, 64, 44–50. [Google Scholar] [CrossRef] [PubMed]
- Ju, R.; Wen, Y.; Gou, R.; Wang, Y.; Xu, Q. The experimental therapy on brain ischemia by improvement of local angiogenesis with tissue engineering in the mouse. Cell Transplant. 2014, 23 (Suppl. 1), S83–S95. [Google Scholar] [CrossRef] [PubMed]
- Lukovic, D.; Moreno-Manzano, V.; Lopez-Mocholi, E.; Rodriguez-Jiménez, F.J.; Jendelova, P.; Sykova, E.; Oria, M.; Stojkovic, M.; Erceg, S. Complete rat spinal cord transection as a faithful model of spinal cord injury for translational cell transplantation. Sci. Rep. 2015, 5, 9640. [Google Scholar] [CrossRef] [PubMed]
- Nicaise, C.; Mitrecic, D.; Falnikar, A.; Lepore, A.C. Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury. World J. Stem Cells 2015, 7, 380–398. [Google Scholar] [CrossRef] [PubMed]
- Aleynik, A.; Gernavage, K.M.; Mourad, Y.S.H.; Sherman, L.S.; Liu, K.; Gubenko, Y.A.; Rameshwar, P. Stem cell delivery of therapies for brain disorders. Clin. Transl. Med. 2014, 3, 24. [Google Scholar] [CrossRef] [PubMed]
- Yuan, T.; Liao, W.; Feng, N.H.; Lou, Y.L.; Niu, X.; Zhang, A.J.; Wang, Y.; Deng, Z.F. Human induced pluripotent stem cell-derived neural stem cells survive, migrate, differentiate, and improve neurologic function in a rat model of middle cerebral artery occlusion. Stem Cell Res. Ther. 2013, 4, 73. [Google Scholar] [CrossRef] [PubMed]
- Kawai, H.; Yamashita, T.; Ohta, Y.; Deguchi, K.; Nagotani, S.; Zhang, X.; Ikeda, Y.; Matsuura, T.; Abe, K. Tridermal tumorigenesis of induced pluripotent stem cells transplanted in ischemic brain. J. Cereb. Blood Flow Metab. 2010, 30, 1487–1493. [Google Scholar] [CrossRef] [PubMed]
- Kelly, S.; Bliss, T.M.; Shah, A.K.; Sun, G.H.; Ma, M.; Foo, W.C.; Masel, J.; Yenari, M.A.; Weissman, I.L.; Uchida, N.; et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc. Natl. Acad. Sci. USA 2004, 101, 11839–11844. [Google Scholar] [CrossRef] [PubMed]
- Kukekov, V.G.; Laywell, E.D.; Suslov, O.; Davies, K.; Scheffler, B.; Thomas, L.B.; O’Brien, T.F.; Kusakabe, M.; Steindler, D.A. Multipotent stem/progenitor cells with similar properties arise from two neurogenic regions of adult human brain. Exp. Neurol. 1999, 156, 333–344. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Y.; Zhang, M.J.; Hu, B.Y. Specification of functional neurons and glia from human pluripotent stem cells. Protein Cell 2012, 3, 818–825. [Google Scholar] [CrossRef] [PubMed]
- Anderson, L.; Burnstein, R.M.; He, X.; Luce, R.; Furlong, R.; Foltynie, T.; Sykacek, P.; Menon, D.K.; Caldwell, M.A. Gene expression changes in long term expanded human neural progenitor cells passaged by chopping lead to loss of neurogenic potential in vivo. Exp. Neurol. 2007, 204, 512–524. [Google Scholar] [CrossRef] [PubMed]
- Fridenshtein, A. Osteogenic stem cells of the bone marrow. Ontogenez 1991, 22, 189–197. [Google Scholar] [PubMed]
- Caplan, A.I. Mesenchymal stem cells. J. Orthop. Res. 1991, 9, 641–650. [Google Scholar] [CrossRef] [PubMed]
- Jankovic, J. Motor fluctuations and dyskinesias in Parkinson’s disease: Clinical manifestations. Mov. Disord. 2005, 20 (Suppl. 11), S11–S16. [Google Scholar] [CrossRef] [PubMed]
- Lindvall, O.; Hagell, P. Clinical observations after neural transplantation in Parkinson’s disease. Prog. Brain Res. 2000, 127, 299–320. [Google Scholar] [PubMed]
- Lindvall, O.; Kokaia, Z. Stem cells for the treatment of neurological disorders. Nature 2006, 441, 1094–1096. [Google Scholar] [CrossRef] [PubMed]
- Lindvall, O.; Rehncrona, S.; Brundin, P.; Gustavii, B.; Astedt, B.; Widner, H.; Lindholm, T.; Björklund, A.; Leenders, K.L.; Rothwell, J.C.; et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 1989, 46, 615–631. [Google Scholar] [CrossRef] [PubMed]
- Liu, Z.; Sakakibara, R.; Odaka, T.; Uchiyama, T.; Yamamoto, T.; Ito, T.; Asahina, M.; Yamaguchi, K.; Yamaguchi, T.; Hattori, T. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov. Disord. 2005, 20, 680–686. [Google Scholar] [CrossRef] [PubMed]
- O’Sullivan, S.S.; Johnson, M.; Williams, D.R.; Revesz, T.; Holton, J.L.; Lees, A.J.; Perry, E.K. The effect of drug treatment on neurogenesis in Parkinson’s disease. Mov. Disord. 2011, 26, 45–50. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez-Nogales, C.; Garbayo, E.; Carmona-Abellán, M.M.; Luquin, M.R.; Blanco-Prieto, M.J. Brain aging and Parkinson’s disease: New therapeutic approaches using drug delivery systems. Maturitas 2015, 84, 25–31. [Google Scholar] [CrossRef] [PubMed]
- Sullivan, K.L.; Staffetti, J.F.; Hauser, R.A.; Dunne, P.B.; Zesiewicz, T.A. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson’s disease. Mov Disord. 2006, 21, 115–116. [Google Scholar] [CrossRef] [PubMed]
- Vorovenci, R.J.; Antonini, A. The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson’s disease. Expert Rev. Neurother. 2015, 15, 1383–1390. [Google Scholar] [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ali, S.A.; Yin, N.; Rehman, A.; Justilien, V. Parkinson Disease-Mediated Gastrointestinal Disorders and Rational for Combinatorial Therapies. Med. Sci. 2016, 4, 1. https://doi.org/10.3390/medsci4010001
Ali SA, Yin N, Rehman A, Justilien V. Parkinson Disease-Mediated Gastrointestinal Disorders and Rational for Combinatorial Therapies. Medical Sciences. 2016; 4(1):1. https://doi.org/10.3390/medsci4010001
Chicago/Turabian StyleAli, Syed A., Ning Yin, Arkam Rehman, and Verline Justilien. 2016. "Parkinson Disease-Mediated Gastrointestinal Disorders and Rational for Combinatorial Therapies" Medical Sciences 4, no. 1: 1. https://doi.org/10.3390/medsci4010001